Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice

European Journal of Pharmacology

Volumn 695, Issue 1-3, 2012, Pages 62-70

  Wiley, Jenny L ^a,b   Marusich, Julie A ^a   Zhang, Yanan ^a   Fulp, Alan ^a   Maitra, Rangan ^a   Thomas, Brian F ^a   Mahadevan, Anu ^c  

^a RTI INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ORGANIX INC   (United States)

Author keywords

(Mouse); Antagonist; Cannabinoid; Feeding; Hemopressin; Pyrazole; Rimonabant; Sulfonamide

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 [4 (HEXAN 2 YL)PHENY] 4 METHYL N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 3 BROMOPROPYL CARBOXAMIDE DERIVATIVE; 3 CYANOPROPYL CARBOXAMIDE DERIVATIVE; 4 (4 CHLOROPHENYL) 3 (2,4 DICHLOROPHENYL) N (PIPERIDIN 1 YL) 5 PROPYLBENZAMIDE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) N [[4 (METHANESULFONAMIDOMETHYL)CYCLOHEXYL]METHYL] 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; 5 [[4 (5 BROMOPENTYL)PHENYL]]PYRAZOLE DERIVATIVE; 6 BROMO 1 (2,4 DICHLOROPHENYL) N (PIPERIDIN 1 YL) 1H INDAZOLE 3 CARBOXAMIDE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; HETERODIMER 6B; N ALLYL CARBOXAMIDE DERIVATIVE; O 1654; O 1690; O 1788; O 2050; O 2154; O 2155; O 3258; O 4373; PYRAZOLE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FOOD INTAKE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; EATING; MALE; MICE; MICE, INBRED ICR; PIPERIDINES; PYRANS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 84867573249     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.08.019     Document Type: Article

References (36)

1. M. Alonso, A. Serrano, M. Vida, A. Crespillo, L. Hernandez-Folgado, N. Jagerovic, P. Goya, C. Reyes-Cabello, V. Perez-Valero, J. Decara, M. Macias-Gonzalez, F.J. Bermudez-Silva, J. Suarez, F.R. de Fonseca, and F.J. Pavon Antiobesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats B. J. Pharmacol. 165 2012 2274 2291
2. C.E. Bass, G. Griffin, M. Grier, A. Mahadevan, R.K. Razdan, and B.R. Martin SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study Pharmacol. Biochem. Behav. 74 2002 31 40
3. W.V. Brown, K. Fujioka, P.W. Wilson, and K.A. Woodworth Obesity: why be concerned? Am. J. Med. 122 2009 S4 S11
4. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
5. F.D. Christopoulou, and D.N. Kiortsis An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity J. Clin. Pharm. Ther. 36 2011 10 18
6. D.R. Compton, M.D. Aceto, J. Lowe, and B.R. Martin In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277 1996 586 594
7. D. Cota, G. Marsicano, B. Lutz, V. Vicennati, G.K. Stalla, R. Pasquali, and U. Pagotto Endogenous cannabinoid system as a modulator of food intake Int. J. Obes. Relat. Metab. Disord. 27 2003 289 301
8. J. De Vry, R. Schreiber, G. Eckel, and K.R. Jentzsch Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A Eur. J. Pharmacol. 483 2004 55 63
9. V. Di Marzo, S.K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, F. Fezza, G.I. Miura, R.D. Palmiter, T. Sugiura, and G. Kunos Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410 2001 822 825
10. G.T. Dodd, G. Mancini, B. Lutz, and S.M. Luckman The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice J. Neurosci. 30 2010 7369 7376
11. A. Fulp, K. Bortoff, Y. Zhang, H. Seltzman, R. Snyder, and R. Maitra Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity Bioorg. Med. Chem. Lett. 21 2011 5711 5714
12. A. Gardner, and P.E. Mallet Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist Eur. J. Pharmacol. 530 2006 103 106
13. R. Gomez, M. Navarro, B. Ferrer, J.M. Trigo, A. Bilbao, I. Del Arco, A. Cippitelli, F. Nava, D. Piomelli, and F. Rodriguez de Fonseca A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding J. Neurosci. 22 2002 9612 9617
14. C.L. Hart, A.S. Ward, M. Haney, S.D. Comer, R.W. Foltin, and M.W. Fischman Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans Psychopharmacology 164 2002 407 415
15. A.S. Heimann, I. Gomes, C.S. Dale, R.L. Pagano, A. Gupta, L.L. de Souza, A.D. Luchessi, L.M. Castro, R. Giorgi, V. Rioli, E.S. Ferro, and L.A. Devi Hemopressin is an inverse agonist of CB1 cannabinoid receptors Proc. Natl. Acad. Sci. U.S.A 104 2007 20588 20593
16. J.E. Koch Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets Pharmacol. Biochem. Behav. 68 2001 539 543
17. S.H. Lockie, T.A. Czyzyk, N. Chaudhary, D. Perez-Tilve, S.C. Woods, B.J. Oldfield, M.A. Statnick, and M.H. Tschop CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice Endocrinology 152 2011 3661 3667
18. J. LoVerme, A. Duranti, A. Tontini, G. Spadoni, M. Mor, S. Rivara, N. Stella, C. Xu, G. Tarzia, and D. Piomelli Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice Bioorg. Med. Chem. Lett. 19 2009 639 643
19. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, R.K. Razdan, M.R. Johnson, L.S. Melvin, R. Mechoulam, and S.J. Ward Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol. Biochem. Behav. 40 1991 471 478
20. P.J. McLaughlin, K. Winston, L. Swezey, A. Wisniecki, J. Aberman, D.J. Tardif, A.J. Betz, K. Ishiwari, A. Makriyannis, and J.D. Salamone The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats Behav. Pharmacol. 14 2003 583 588
21. National Research Council, 1996, Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, D.C.
22. M. Poncelet, J. Maruani, R. Calassi, and P. Soubrie Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice Neurosci. Lett. 343 2003 216 218
23. A.G. Powell, C.M. Apovian, and L.J. Aronne New drug targets for the treatment of obesity Clin. Pharmacol. Ther. 90 2011 40 51
24. C. Ravinet Trillou, C. Delgorge, C. Menet, M. Arnone, and P. Soubrie CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int. J. Obes. Relat. Metab. Disord. 28 2004 640 648
25. N.E. Rowland, M. Mukherjee, and K. Robertson Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats Psychopharmacology 159 2001 111 116
26. P.K. Sasmal, R. Talwar, J. Swetha, D. Balasubrahmanyam, B. Venkatesham, K.A. Rawoof, B. Neelima Devi, V.P. Jadhav, S.K. Khan, P. Mohan, D. Srinivasa Reddy, V.K. Nyavanandi, S. Nanduri, K. Shiva Kumar, M. Kannan, P. Srinivas, P. Nadipalli, H. Chaudhury, and V.J. Sebastian Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists Bioorg. Med. Chem. Lett. 21 2011 4913 4918
27. V.M. Showalter, D.R. Compton, B.R. Martin, and M.E. Abood Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands J. Pharmacol. Exp. Ther. 278 1996 989 999
28. A.N. Verty, I.S. McGregor, and P.E. Mallet Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats Neurosci. Lett. 354 2004 217 220
29. S.P. Vickers, L.J. Webster, A. Wyatt, C.T. Dourish, and G.A. Kennett Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats Psychopharmacology 167 2003 103 111
30. J.L. Wiley, C.S. Breivogel, A. Mahadevan, R.G. Pertwee, M.G. Cascio, D. Bolognini, J.W. Huffman, D.M. Walentiny, R.E. Vann, R.K. Razdan, and B.R. Martin Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist Eur. J. Pharmacol. 651 2011 96 105
31. J.L. Wiley, J.J. Burston, D.C. Leggett, O.O. Alekseeva, R.K. Razdan, A. Mahadevan, and B.R. Martin CB1 cannabinoid receptor-mediated modulation of food intake in mice B. J. Pharmacol. 145 2005 293 300
32. J.L. Wiley, R.G. Jefferson, M.C. Grier, A. Mahadevan, R.K. Razdan, and B.R. Martin Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation J. Pharmacol. Exp. Ther. 296 2001 1013 1022
33. J.L. Wiley, D.E. Selley, P. Wang, R. Kottani, S. Gadthula, and A. Mahadeven 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB1) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB1, non-CB2 mechanism J. Pharmacol. Exp. Ther. 340 2012 433 444
34. C.M. Williams, and T.C. Kirkham Observational analysis of feeding induced by Delta9-THC and anandamide Physiol. Behav. 76 2002 241 250
35. C.M. Williams, P.J. Rogers, and T.C. Kirkham Hyperphagia in pre-fed rats following oral delta9-THC Physiol. Behav. 65 1998 343 346
36. Y. Zhang, A. Gilliam, R. Maitra, M.I. Damaj, J.M. Tajuba, H.H. Seltzman, and B.F. Thomas Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 53 2010 7048 7060